Hamburg, Germany - 15 October 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of EUR 4.0 m to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'This is the twentieth milestone achieved as part of our alliance with Boehringer Ingelheim and represents a second oncology compound transitioning into pre-clinical development. I would like to congratulate the teams from both companies on their continuing excellent progress in the collaboration.' 

ABOUT THE EVOTEC & BOEHRINGER INGELHEIM ALLIANCE

In 2004, Evotec entered into a multi-year, multi-target drug discovery alliance with Boehringer Ingelheim to jointly identify and develop pre-clinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases. In 2009, the collaboration was extended for an additional four years and the scope expanded to include oncology targets. Under the terms of the agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialisation of the compounds identified. In return, Evotec receives ongoing research payments and pre-clinical milestones. Furthermore, the contract provides substantial long-term upside for Evotec through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.